Cargando…
Overview of the relevance of PI3K pathway in HR-positive breast cancer
One of the hallmarks of hormone receptor (HR)-positive breast cancer is its dependence on the phosphatidylinositol-3-kinase (PI3K) pathway. Here, we review the epidemiologic, functional, and pharmacologic interactions between oncogenic PI3K and the estrogen receptor (ER). We discuss the epidemiology...
Autores principales: | Vasan, N, Toska, E, Scaltriti, M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923788/ https://www.ncbi.nlm.nih.gov/pubmed/31859348 http://dx.doi.org/10.1093/annonc/mdz281 |
Ejemplares similares
-
The present and future of PI3K inhibitors for cancer therapy
por: Castel, Pau, et al.
Publicado: (2021) -
Chromatin regulation at the intersection of estrogen receptor and PI3K pathways in breast cancer
por: Castel, Pau, et al.
Publicado: (2019) -
Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements
por: Bertucci, Alexandre, et al.
Publicado: (2023) -
The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments
por: Presti, Daniele, et al.
Publicado: (2019) -
The Predictive Role of PIK3CA Mutation Status on PI3K Inhibitors in HR+ Breast Cancer Therapy: A Systematic Review and Meta-Analysis
por: Wang, Mingming, et al.
Publicado: (2020)